BioNTech Buys CureVac in $1.25 Billion mRNA Cancer Bet
BioNTech has agreed to acquire German biotech rival CureVac in a $1.25 billion all-stock deal, strengthening its ambitions in mRNA-based...
Read moreDetailsBioNTech has agreed to acquire German biotech rival CureVac in a $1.25 billion all-stock deal, strengthening its ambitions in mRNA-based...
Read moreDetailsThe U.S. Treasury yield is expected to decrease in the coming months as investors predict the Federal Reserve will cut...
Read moreDetailsPtsident Trump announced on Wednesday that the U.S.-China trade agreement is finalized but many details remain unclear. Through his Truth...
Read moreDetailsuThe $24.7 billion withdrawal from U.S. stock funds by global investors during May occurud because they moved their money to...
Read moreDetailsThe World Bank reduced its 2025 global economic growth projection because rising tariffs together with increasing economic uncertainty create major...
Read moreDetails